Pharmacological management of erectile dysfunction

Research output: Contribution to journalArticlepeer-review


Erectile dysfunction is a common sexual dysfunction, with an estimated prevalence of 8% among men aged 40 years and 40% among men aged 60 years. It is associated with cardiovascular risk factors. Treatment is commonly with ‘as required’ or daily phosphodiesterase type 5 inhibitors: sildenafil citrate, tadalafil, or vardenafil, although other options are available. The selection of treatment is dependent on accurate assessment, estimation of cardiovascular risk, and patient choice. In this article, treatment choices are considered and strategies for optimizing treatment are recommended.
Original languageEnglish
Pages (from-to)339-344
JournalNurse Prescribing
Issue number7
Publication statusPublished - 1 Jul 2012
Externally publishedYes


  • Erectile Dysfunction
  • ED
  • cardiovascular disease risk factors
  • treatment
  • pharmacological interventions
  • clinical management


Dive into the research topics of 'Pharmacological management of erectile dysfunction'. Together they form a unique fingerprint.

Cite this